Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JONATHAN SIEGEL

NPI
1639110224
CMS profile
1288429
Location
MOBILE, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$2,831.63

177 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,831.63 177

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 177 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JONATHAN SIEGEL

NPI 1639110224 · CMS profile ID 1288429

MOBILE, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 177 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1639110224?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JONATHAN SIEGEL, NPI 1639110224, CMS profile ID 1288429. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 177 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1639110224?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). JONATHAN SIEGEL, NPI 1639110224, CMS profile ID 1288429. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 177 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1639110224?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
JONATHAN SIEGEL, NPI 1639110224, CMS profile ID 1288429, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 177 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1639110224?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

177 matching records · $2,831.63 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 177 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 177.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Salix Pharmaceuticals, a division of Bausch Health US, LLC $13.5105/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153637648 CMS
GENZYME CORPORATION $35.3905/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139704751 CMS
Janssen Biotech, Inc. $14.0205/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078262647 CMS
Braintree Laboratories, Inc. $15.8105/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125517863 CMS
PFIZER INC. $5.7605/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131565034 CMS
ABBVIE INC. $14.1905/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106100333 CMS
Ardelyx, Inc. $24.3105/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146708090 CMS
ABBVIE INC. $10.9405/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106100331 CMS
ABBVIE INC. $12.5205/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106100329 CMS
GENZYME CORPORATION $27.3405/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139704739 CMS
ABBVIE INC. $16.1405/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106100327 CMS
ABBVIE INC. $21.3205/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106100325 CMS
Janssen Biotech, Inc. $17.9905/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078260897 CMS
Phathom Pharmaceuticals, Inc. $14.5805/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151126197 CMS
ABBVIE INC. $12.8505/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106100323 CMS
Janssen Biotech, Inc. $13.8104/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078261123 CMS
Takeda Pharmaceuticals U.S.A., Inc. $21.3004/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137676151 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $15.3504/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153693162 CMS
ABBVIE INC. $18.1504/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106100321 CMS
Lilly USA, LLC $18.3604/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135095512 CMS
Braintree Laboratories, Inc. $17.4004/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125517861 CMS
Janssen Biotech, Inc. $13.8204/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078263053 CMS
Ardelyx, Inc. $32.7004/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146708088 CMS
ABBVIE INC. $6.3804/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106100319 CMS
Phathom Pharmaceuticals, Inc. $15.1204/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151126195 CMS
IRONWOOD PHARMACEUTICALS, INC $19.6004/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153752784 CMS
GENZYME CORPORATION $25.2404/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139704733 CMS
SHIELD THERAPEUTICS INC $15.5604/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150126883 CMS
ABBVIE INC. $13.1004/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106100317 CMS
ABBVIE INC. $14.6304/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106100315 CMS
Phathom Pharmaceuticals, Inc. $14.2204/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151126193 CMS
Janssen Biotech, Inc. $18.1803/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078261505 CMS
Merck Sharp & Dohme LLC $15.4703/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141695498 CMS
Regeneron Healthcare Solutions, Inc. $24.5903/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114172504 CMS
Ardelyx, Inc. $24.7903/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146708086 CMS
IRONWOOD PHARMACEUTICALS, INC $19.5203/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153708664 CMS
ABBVIE INC. $15.8603/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106100313 CMS
Medtronic, Inc. $15.6903/18/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1246918353 CMS
ABBVIE INC. $22.6803/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106100311 CMS
AIMMUNE THERAPEUTICS, INC. $13.4903/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147021447 CMS
ABBVIE INC. $16.7503/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106100309 CMS
ABBVIE INC. $4.3803/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106100307 CMS
GENZYME CORPORATION $24.5703/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139704727 CMS
Phathom Pharmaceuticals, Inc. $17.3103/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151126191 CMS
Janssen Biotech, Inc. $14.2803/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078263199 CMS
ABBVIE INC. $17.3603/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106100305 CMS
IRONWOOD PHARMACEUTICALS, INC $14.6102/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153726302 CMS
GENZYME CORPORATION $28.5302/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139704719 CMS
Janssen Biotech, Inc. $22.0502/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078260783 CMS
Takeda Pharmaceuticals U.S.A., Inc. $14.7402/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137676149 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,396.72 96
PY2020 $781.46 55
PY2021 $1,842.42 119
PY2022 $2,724.37 196
PY2023 $2,277.94 152
PY2024 $2,831.63 177
PY2025 $2,838.18 175

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $395,546.57 43
PY2024 Principal investigator $310,314.30 39
PY2023 Principal investigator $730,625.65 54
PY2022 Principal investigator $234,547.56 85
PY2021 Principal investigator $160,768.95 54
PY2020 Principal investigator $499,540.02 152
PY2019 Principal investigator $262,861.76 96

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

43 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $15,000.00 12/17/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
Study of DONQ52 in Active Celiac Disease No dispute reported 06/30/2026 1211600210
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $3,500.00 12/17/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
Study of DONQ52 in Active Celiac Disease No dispute reported 06/30/2026 1211600214
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $3,000.00 12/17/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
Study of DONQ52 in Active Celiac Disease No dispute reported 06/30/2026 1211600222
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $1,500.00 12/17/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
Study of DONQ52 in Active Celiac Disease No dispute reported 06/30/2026 1211600227
Principal investigator 1 ABBVIE INC. $2,500.00 12/11/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202530144
Principal investigator 1 ABBVIE INC. $1,560.35 12/11/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202530146
Principal investigator 1 ABBVIE INC. $731.53 12/04/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202528130
Principal investigator 1 ABBVIE INC. $260.35 12/02/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202526296
Principal investigator 1 ABBVIE INC. $11,340.00 11/26/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202525442
Principal investigator 1 ABBVIE INC. $15,041.71 10/09/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202515899
Principal investigator 1 ABBVIE INC. $33,210.00 09/16/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202511068
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11,000.00 09/10/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) No dispute reported 06/30/2026 1223285177
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,500.00 09/10/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) No dispute reported 06/30/2026 1223285207
Principal investigator 1 ABBVIE INC. $1,213.25 09/03/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202508200
Principal investigator 1 PFIZER INC. $1,200.00 09/03/2025 Non-covered Recipient Entity
East View Medical Research LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228834869
Principal investigator 1 PFIZER INC. $1,836.00 09/03/2025 Non-covered Recipient Entity
East View Medical Research LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228834874
Principal investigator 1 PFIZER INC. $2,000.00 09/03/2025 Non-covered Recipient Entity
East View Medical Research LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228834878
Principal investigator 1 ABBVIE INC. $25.00 08/26/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
A Long-Term Registry of Humira (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202505945
Principal investigator 1 ABBVIE INC. $5,892.76 08/06/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202502663
Principal investigator 1 ABBVIE INC. $21,000.00 08/06/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) No dispute reported 06/30/2026 1202502665
Principal investigator 1 ABBVIE INC. $8,816.60 07/02/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202495171
Principal investigator 1 ABBVIE INC. $276.75 07/02/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202495173
Principal investigator 1 ABBVIE INC. $33,210.00 06/11/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202490887
Principal investigator 1 ABBVIE INC. $8,367.00 06/03/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202489055
Principal investigator 1 Genentech, Inc. $851.00 05/23/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211600244
Principal investigator 1 PFIZER INC. $813.00 05/23/2025 Non-covered Recipient Entity
East View Medical Research LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228849396
Principal investigator 1 PFIZER INC. $1,013.00 05/23/2025 Non-covered Recipient Entity
East View Medical Research LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228850037
Principal investigator 1 PFIZER INC. $750.00 05/23/2025 Non-covered Recipient Entity
East View Medical Research LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228850314
Principal investigator 1 PFIZER INC. $300.00 05/23/2025 Non-covered Recipient Entity
East View Medical Research LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228850398
Principal investigator 1 PFIZER INC. $14,812.00 05/23/2025 Non-covered Recipient Entity
East View Medical Research LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228850405
Principal investigator 1 ABBVIE INC. $8,584.20 05/07/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202482675
Principal investigator 1 Genentech, Inc. $130,203.00 04/23/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211600247
Principal investigator 1 PFIZER INC. $1,457.00 04/11/2025 Non-covered Recipient Entity
East View Medical Research LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228850142
Principal investigator 1 ABBVIE INC. $4,774.48 04/03/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202471676
Principal investigator 1 PFIZER INC. $801.00 03/17/2025 Non-covered Recipient Entity
East View Medical Research LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228854110
Principal investigator 1 PFIZER INC. $1,775.00 03/17/2025 Non-covered Recipient Entity
East View Medical Research LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228854117
Principal investigator 1 ABBVIE INC. $1,213.25 03/06/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
M14-430 - A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202458043
Principal investigator 1 Genentech, Inc. $2,684.00 02/26/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211600235
Principal investigator 1 Genentech, Inc. $2,020.00 02/19/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211600240
Principal investigator 1 PFIZER INC. $3,357.00 02/03/2025 Non-covered Recipient Entity
East View Medical Research LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228854085
Principal investigator 1 ABBVIE INC. $6,456.94 01/21/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn Disease (CD) No dispute reported 06/30/2026 1202440459
Principal investigator 1 Genentech, Inc. $27,232.00 01/13/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211600231
Principal investigator 1 ABBVIE INC. $1,468.40 01/02/2025 Non-covered Recipient Entity
EAST VIEW MEDICAL RESEARCH LLC
M14-430 - A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202434099